Related by context. All words. (Click for frequent words.) 67 phase IIIb 66 CRMD# 66 PFO migraine 66 Phase Ib II 65 oral ridaforolimus 65 Phase Ib study 65 SUCCEED trial 65 Phase IIB 64 Phase Ib clinical 64 Phase 1b trial 64 phase IIb trial 64 ENDEAVOR IV 64 BRIM3 64 Phase IIb III 64 phase Ib 63 preclinical efficacy 63 Zenvia Phase III 63 clevidipine 63 CUSTOM III 63 AVADO 63 ENDEAVOR III 63 phase IIa 63 ADAGIO study 63 APEX AMI trial 63 HORIZONS AMI trial 63 PANVAC VF 63 MEND CABG 63 rALLy trial 63 fosbretabulin 63 SABCS 63 PEARL SC 63 skin sterol 63 Confirmatory 62 CHAMPION PCI 62 NO# [002] 62 confirmatory clinical 62 AVERROES 62 RE LY 62 clinical pharmacology studies 62 APEX PD 62 HuMax EGFr 62 phase IIa clinical 62 EchoCRT 62 SIMPADICO 62 MERLIN TIMI 62 QTinno 62 preclinically 62 VerifyNow P#Y# 62 pharmacokinetic PK study 62 BrachySil TM 62 STRIDE PD 62 ASSERT trial 62 PERSEUS 62 AIM HIGH 62 ACCLAIM II 62 Phase IIIb clinical 62 neratinib 62 APPRAISE 62 randomized Phase IIb 62 MAGE A3 ASCI 62 pharmacodynamic PD 61 Phase 1a clinical 61 Phase #b/#a 61 Phase IIb clinical trials 61 multicenter Phase 61 multicenter randomized clinical 61 Phase 2b study 61 mg/m2 cohort 61 novel oral anticoagulant 61 MIST II 61 randomized Phase 2b 61 pain palliation 61 SPIRIT FIRST 61 Phase #b/#a clinical 61 Trofex 61 AZILECT ® 61 Prospective Randomized 61 varespladib 61 ADVANCE PD 61 Phase IIb trials 61 vidofludimus 61 TLK# 61 phase IIb clinical 61 Thorough QT 61 PIX# [002] 60 INCB# [001] 60 Kamada AAT 60 PD2i ® 60 BLA filing 60 pharmacokinetic PK 60 fidaxomicin Phase 60 thorough QT 60 Phase #/#a 60 CRLX# 60 Phase 2a trial 60 pharmacodynamic effects 60 placebo controlled clinical 60 Hedgehog antagonist 60 phase IIb 60 BARI 2D 60 Aggressive Drug Evaluation 60 CLIRS trial 60 APTIMA HPV assay 60 viral kinetics 60 REVIVE Diabetes 60 Panzem R NCD 60 RE COVER 60 EOquin TM 60 registrational 60 phase IIb study 60 unblind 60 PROactive study 60 PD2i 60 CA9 SCAN 60 LUX Lung 60 EmbraceAC 60 viral kinetic 60 Phase IIIb study 60 ZOLINZA 60 Hyphanox 60 Xelox 60 multicenter clinical 60 RE LY ® 60 azilsartan medoxomil 60 ENGAGE AF TIMI 60 lintuzumab 60 Elocalcitol 60 genotypic resistance 60 eTag assays 60 Dyloject TM 60 efficacy endpoint 60 Acute Ischemic Stroke 60 Augment Injectable 60 placebo controlled Phase III 60 randomized multicenter trial 60 ACRIN 60 alvespimycin 60 Phase #/#a clinical 60 Tesmilifene 60 GOUT 60 MAA submission 60 ruxolitinib 60 Phase III psoriasis 60 MyVax personalized immunotherapy 59 VESTAsync 59 ABSORB trial 59 BCIRG 59 PARTNER Trial 59 trastuzumab emtansine T DM1 59 CLORETAZINE TM VNP#M 59 REMINYL ® 59 SYMMETRY trial 59 R# #mg BID 59 OvaRex 59 enzastaurin 59 favorable pharmacokinetic profile 59 bevirimat Study 59 Ophena 59 pharmacokinetics PK 59 CAPHOSOL 59 APTIVUS 59 OvaRex MAb 59 randomized controlled Phase 59 CHARM Added 59 farletuzumab 59 PEG SN# 59 OvaRex ® MAb 59 CardioFit 59 plasma kallikrein inhibitor 59 Surgical Mesh 59 LUMINATE 59 GAMMAGARD 59 Maximum Tolerated Dose MTD 59 ACCLAIM 59 RLY# 59 Azedra 59 GENASIS trial 59 LibiGel Phase III 59 secondary efficacy endpoints 59 NP2 Enkephalin 59 miRview mets 59 AZILECT R 59 neoadjuvant treatment 59 optimal dosing 59 dosing cohort 59 brivaracetam 59 Phase III confirmatory 59 CLIRS 59 PRECISE 59 BLP# Liposome Vaccine 59 blinded randomized placebo controlled 59 Pivotal Study 59 MEND CABG II 59 RenalGuard System TM 59 Phase 2b clinical trials 59 NEO3 59 efficacy tolerability 59 Phase III Clinical Trial 59 oral FTY# 59 PMA submission 59 pharmacokinetic PK profile 59 LibiGel ® 59 Raptiva ® 59 pharmacodynamic properties 59 OvaRex R 59 NSABP B 59 OvaDx 59 multicentre randomized 59 CURE AF 59 epoetin alpha 59 KRAS status 59 unblinding 59 ONTARGET 59 trastuzumab DM1 T DM1 59 neoadjuvant 59 GFT# 59 PFO closure 59 ExTRACT TIMI 59 arzoxifene 59 CARE HF 59 prospective multicentre 58 antiviral efficacy 58 Pivotal Clinical Trial 58 ENESTnd 58 GetGoal Phase III 58 EDEMA3 58 riociguat 58 Phase IIa trials 58 DSMB recommended 58 PRECISE trial 58 multicenter randomized controlled 58 NADiA ProsVue 58 carotid endarterectomy CEA 58 PROLARIS 58 prospective multicenter randomized 58 COSIRA trial 58 Xanafide 58 IIa trial 58 QTinno TM 58 OLYMPIA registry 58 Phase IIa trial 58 VNP#M 58 PRESEPT 58 balsalazide tablet 58 Archexin 58 Plenaxis TM 58 Extina 58 QuadraSphere 58 BEXXAR 58 Phase #b/#a trial 58 nab paclitaxel 58 multicenter trials 58 HCV SPRINT 58 UPLYSO 58 Viramidine 58 dipyridamole plus 58 confirmatory Phase III 58 GORE VIABAHN Endoprosthesis 58 Urocortin 2 58 Feasibility Trial 58 randomized Phase III 58 HDL Selective Delipidation 58 Cloretazine ® 58 Phase IIIb 58 DNA methylation markers 58 BREVAGen ™ 58 velafermin 58 NOX E# 58 PROSTVAC TM 58 Capesaris 58 CLARITY study 58 treatment naive genotype 58 Phase 2b kidney transplant 58 HepaSphere 58 GLP toxicology studies 58 Phase 2a clinical trials 58 StemEx 58 ONCONASE R 58 CALGB 58 Octreolin 58 axitinib 58 inhaled AAT 58 OvPlex ™ 58 VITAL Trial 58 PSMA ADC 58 ENDEAVOR II 58 Phase III HEAT 58 TASKi3 58 Platelet Inhibition 58 Renal Cell Carcinoma RCC 58 Oncotype DX colon cancer 58 PREOS R 58 ImmuKnow R 58 VTE prevention 58 Traficet EN 58 multicenter Phase II 58 XL# SAR# 58 SUPERA stent 58 PROSTVAC ® 58 noninferiority 58 sunitinib malate 58 mSEPT9 58 PACCE 58 adjuvant endocrine therapy 58 TOLAMBA 58 crizotinib PF # 58 ZACTIMA 58 TRO# 58 DASISION 58 prospective observational cohort 58 VerifyNow 58 dose cohort 58 subgroup analyzes 58 Genz # 58 MGN# 58 ATACAND 58 ILLUMINATE 58 Phase III multicenter 58 BioSTAR R 58 NATRECOR ® 58 PEG IFN 58 multicenter prospective 58 Clinical Outcomes Utilizing Revascularization 58 CHARISMA trial 58 Phase 1b clinical trials 58 biostatistical analysis 58 Randomized Evaluation 57 dose escalation Phase 57 HERmark 57 Glufosfamide 57 rALLy clinical trial 57 Ranolazine 57 ZYBRESTAT TM 57 Androxal TM 57 EMPHASIS HF 57 tramiprosate Alzhemed TM 57 vernakalant hydrochloride 57 MGd 57 pivotal bioequivalence 57 registrational trial 57 Vaxfectin TM 57 Randomized controlled 57 Prostate AdenoCarcinoma Treatment 57 Spartan RX CYP#C# 57 abiraterone acetate 57 aleglitazar 57 EXPLORE Xa 57 pertuzumab 57 DermaVir Patch 57 MelaFind pivotal 57 lorcaserin Phase 57 HGS# 57 European Sepsis Trial 57 dose escalation clinical 57 AZOR 57 Telatinib 57 BENICAR HCT 57 Liprostin 57 phase IIb III 57 ganetespib 57 CoFactor 57 Pharmacodynamic 57 NeuroFlo 57 IN.PACT 57 zotarolimus eluting stent 57 ADMIRE HF 57 PRIMO CABG2 57 PROACT 57 Dose escalation 57 Pivotal Trial 57 UroVysion 57 Phase III ThermoDox 57 BREVAGen 57 analgesic efficacy 57 NCIC CTG 57 budesonide foam 57 Anturol TM 57 depsipeptide 57 indibulin 57 Phase #/#a trial 57 controlled multicenter Phase 57 DermTech International 57 INTERCEPT platelets 57 Q#IR 57 Dacogen injection 57 Multicenter 57 dosage regimens 57 MIRCERA 57 PCA3 assay 57 ANCHOR trial 57 EXPAREL ™ 57 peg interferon 57 ThermoDox ® clinical 57 Phase III randomized controlled 57 Aurexis 57 ToGA 57 IIa clinical 57 PD2i R 57 durable pain palliation 57 MYTHOS trial 57 Vitaxin 57 prospective multicenter 57 dose proportionality 57 Pivotal Phase III 57 PRADAXA 57 MYDICAR 57 Silodosin 57 inhibitor RG# 57 Dr. Yatscoff 57 tanespimycin 57 NEVO TM 57 dual endothelin receptor antagonist 57 Insulin PH# 57 Primary endpoints 57 Pharmacokinetic PK 57 Chemophase 57 SILENOR 57 deforolimus 57 Delcath Phase III 57 MADIT 57 ongoing Phase 1b 57 BRIM2 57 Phase Ib 57 YONDELIS 57 Catena ® 57 Degarelix 57 ritonavir boosted danoprevir 57 Pharmacokinetic parameters 57 NEVO ™ 57 NSABP 57 Phase 2b randomized 57 PROMACTA 57 tipranavir 57 XmAb# 57 Cervista HPV HR 57 forodesine 57 CTAP# Capsules 57 phase 2a 57 Phase IIB clinical 57 oral PrEP 57 prospective multicenter study 57 IMPACT DCM 57 SEPET TM 57 Phase 1b 57 adecatumumab 57 clinicaltrials 57 GEM OS2 57 Allovectin 7 ® 57 subanalysis 57 prasugrel Effient 57 Phase 2a 57 OZURDEX 57 Oncotype 57 ATAC Arimidex Tamoxifen Alone 57 TAXUS ATLAS 57 Elitek 57 QTinno ™ 57 assessing T DM1 57 ACAPODENE 57 aplindore 57 TAXUS IV 57 ELACYT 57 Fibrillex TM 57 TQT 57 endothelin antagonists 57 tolevamer 57 Phase 2b clinical 57 oral picoplatin 57 Phase 1b clinical 57 RE SURGE 57 StemEx R 57 Zenvia ™ 57 SIR Spheres 57 JenaValve 57 Telintra 57 Phase 1a 57 plasma pharmacokinetics 56 Phase III ADT 56 cortical stimulation 56 sipuleucel T 56 Plicera 56 PTNS 56 EMPHASIS HF trial 56 AEGR 56 Zybrestat 56 Septin9 56 pharmacokinetic equivalence 56 lomitapide 56 oral salmon calcitonin 56 Phase 2b trial 56 SPIRIT IV 56 eprotirome 56 DEEP AF 56 fidaxomicin Phase 3 56 Edwards SAPIEN valve 56 IRX 2 56 sNDA submission 56 ASCEND HF 56 Dr. Pingpank 56 MammaPrint ® 56 nonclinical studies 56 Bezielle 56 ReN# 56 dose escalation phase 56 Inhaled AAT 56 pharmacodynamic endpoints 56 PreCISe 56 Percutaneous Tibial Nerve Stimulation 56 MVax 56 OnDose 56 pharmacokinetic pharmacodynamic 56 Cologuard 56 Phase Ib IIa 56 PLCO 56 Endeavor drug eluting 56 Clinical Trial Results 56 pioglitazone HCl 56 Sirolimus eluting 56 Phase III Pivotal 56 LungExpress Dx TM 56 ixabepilone 56 ACCORD Lipid 56 TEMSO 56 Phase 2a clinical 56 CINTREDEKIN BESUDOTOX 56 Phase lll 56 Phase IIb Clinical Trial 56 cerebral oximetry 56 Ophena TM 56 PREOS 56 Phase III pivotal 56 cangrelor 56 TM Drug Eluting 56 Aplidin 56 ARCOXIA 56 VESTASYNC 56 registrational Phase 56 DDP# 56 lumiliximab 56 MoxDuo IR 56 morphometric vertebral fractures 56 teriflunomide 56 IND submission 56 DAPT 56 myocardial revascularization 56 preclinical pharmacokinetic 56 ID NCT# 56 MabCampath 56 ARIXTRA 56 elotuzumab 56 renal artery stenting 56 ELCAP 56 Orazol 56 romidepsin 56 LightTouch 56 identifier NCT# 56 desvenlafaxine succinate 56 AVONEX PEN 56 Teysuno 56 AdnaTest 56 RX ACCULINK 56 PCI ExTRACT TIMI 56 Arikace 56 sargramostim 56 GW# [003] 56 Phase III TRIST 56 SUTENT ® 56 Radient Pharmaceutical current 56 cobiprostone 56 Tumor Response 56 IIa trials 56 ORMD 56 Pharmacokinetic studies 56 ImmuKnow 56 Mr. Rosconi 56 Phase III Psoriasis 56 Subgroup analysis 56 Pharmacokinetic 56 Combination REOLYSIN R 56 TOCOSOL Paclitaxel 56 CIMZIA TM 56 radiation dosimetry 56 REG1 56 Hsp# Inhibitor 56 multicenter phase 56 PD2i CA 56 Oncotype DX Recurrence Score 56 elacytarabine 56 Vilazodone 56 pradefovir 56 MiDAS 56 ROCKET AF 56 PGxPredict 56 VADT 56 Initiated Phase 56 placebo controlled Phase 56 Aflibercept 56 TAXUS V 56 myocardial necrosis 56 Initiate Phase II 56 ongoing Phase IIIb 56 IIb clinical trial 56 AQ4N 56 torezolid phosphate 56 Resolute DES 56 RESTORE CLI 56 Phase IIb 56 secondary efficacy endpoint 56 LEUKINE 56 pharmacokinetic studies 56 randomized multicenter Phase III 56 BioMatrix TM 56 RE LY trial 56 Urocidin 56 NABTT 56 Cand5 56 AVASTIN 56 COMFORT II 56 drug eluting stent DES 56 REALITY Trial 56 bicifadine 56 urocortin 2 56 transesophageal echocardiography TEE 56 CAMMS# 56 PegIFN RBV 56 ularitide 56 Tarceva TM 56 IMA# 56 JAK inhibitor 56 HoFH 56 Alvesco R 56 AVAX 56 TAXUS Liberte Stent 56 BGC# 56 Pimavanserin 56 ORENCIA R 56 PSN# [002] 56 Phase Ia 56 X PECT trial 56 ticagrelor Brilinta 56 pharmacogenetic testing 56 Corgentin 56 Bicifadine 56 RE MODEL 56 vorinostat 56 TMC# [002] 56 ACUITY trial 56 substudy 56 torcetrapib atorvastatin 56 miRview ™ mets 56 Allovectin 7 56 ALTROPANE 56 EVEREST II 56 alvimopan 56 Pertuzumab 56 ORENCIA ® 56 multicenter clinical trials 56 BioSante LibiGel Phase III 56 platelet inhibitor 56 TactiCath 56 GEM OS1 56 ARIKACE 56 Phase 2b RESTORE CLI 56 doxorubicin docetaxel 56 Mammastatin Serum Assay 56 MTWA testing 56 ® pioglitazone HCl 56 Phase Ib Clinical Trial 56 cannabinor 56 LE SN# 56 ISEL 56 Spiriva Handihaler 56 multicenter Phase III 56 RAPAFLO R 56 antithrombotic therapy 56 phase Ib clinical 56 faropenem 56 liposomal formulation 56 carotid artery stenting 56 Medifacts 56 radiographic outcomes 56 OMNARIS Nasal Spray 56 Dabigatran etexilate 56 TASKi2 56 Clolar ® 56 NCCTG 56 QLT# 56 Vernakalant 56 pharmacodynamics PD 56 sorafenib Nexavar 56 mertansine 56 prucalopride 55 eculizumab therapy 55 evaluating mipomersen 55 e2 Collector 55 Viprinex TM 55 NV1FGF 55 ARISE Phase III 55 initiate Phase Ib 55 multicenter randomized Phase 55 Cardiotoxicity 55 Phase 2b Clinical Trial 55 Pafuramidine 55 NDA resubmission 55 BST CarGel R 55 Personalized Immunotherapy 55 refractory CLL 55 Xience Prime 55 OMAPRO ™ 55 cariprazine 55 lorvotuzumab mertansine 55 TREDAPTIVE 55 Corus CAD 55 EVIZON 55 SNT MC# 55 Harry Palmin President 55 Delcath PHP System 55 Vascugel ® 55 pharmacokinetic parameters 55 ImmuKnow assay 55 Perforomist ™ Inhalation Solution 55 nanopharmaceutical 55 randomized controlled clinical trials 55 PROSTASCINT R 55 rNAPc2 55 Myocet 55 OMAPRO 55 retrospective observational study 55 Vascular Wrap 55 EURIDIS 55 elagolix 55 miRview meso 55 angiographic outcomes 55 Electronic Brachytherapy 55 PRoFESS 55 DU #b 55 novel VDA molecule 55 tesmilifene 55 samalizumab 55 Afatinib 55 Excellagen 55 pexiganan 55 PRECiSE 55 Mammostrat 55 Eluting Coronary Stent System 55 omacetaxine mepesuccinate 55 BioZ ICG 55 Phase IIb clinical 55 CytoFabTM 55 label multicenter Phase 55 ATTRACT 55 everolimus eluting stents 55 Anticalin ® 55 Placebo Controlled Trial 55 Neovasc Reducer 55 immunohistochemical 55 zanolimumab 55 Quinamed 55 OVATURE 55 cardiac repolarization 55 maximally tolerated dose 55 Secondary efficacy endpoints 55 randomized controlled clinical 55 Apoptone 55 Tectin TM 55 RECIST Response Evaluation Criteria 55 EDEMA3 trial 55 SinuNase ™ 55 Adverse Event 55 Ascendra 55 ABLAVAR ® 55 ritonavir boosted 55 apremilast 55 Abciximab 55 Asentar 55 oral taxane 55 unblinded 55 concurrent chemoradiation 55 HCV RESPOND 2 55 CURRENT OASIS 7 55 eniluracil 55 NEUVENGE 55 EDEMA4 55 HDAC Inhibitor 55 EFAPROXYN 55 CORD II 55 CR# vcMMAE 55 DES implantation 55 Ixempra 55 resminostat 55 trastuzumab DM1 55 clinically meaningful efficacy 55 Neurostep TM 55 TAXUS VI 55 confirmatory Phase 3 55 Ceplene/IL-2 55 ZYBRESTAT fosbretabulin 55 incyclinide 55 Phase III LibiGel 55 Phase 1b dose escalation 55 intradermal injections 55 PROVENGE ® 55 CALGB # [002] 55 vivo potency 55 Ketotransdel 55 RIGScan CR 55 Microwave Ablation System 55 Dacogen TM 55 trodusquemine 55 Efficacy Results 55 immunotherapeutic vaccine 55 irbesartan 55 cytoreductive nephrectomy 55 HuCAL antibodies 55 Lp PLA 2 55 Sorafenib HCC Assessment 55 NSABP C 55 CBLC# 55 basal bolus regimen 55 AIMM trial 55 Cloretazine 55 relapsed MM 55 p# biomarker 55 TACI Ig 55 Androxal ® 55 pharmacodynamic markers 55 COPERNICUS 55 MacuSight 55 bepotastine besilate nasal spray 55 PRIMO CABG 55 Poly ICLC 55 co receptor tropism 55 Endarterectomy 55 Onrigin 55 VFEND 55 APTIVUS R 55 resynchronization therapy 55 Flow cytometry 55 epigenetic therapies 55 BioMarck 55 Custom NX 55 nonrandomized 55 FACTIVE tablets 55 microplasmin Phase III 55 ABCSG 55 MADIT CRT 55 Angiox R 55 bendamustine 55 Optical Coherence Tomography 55 Solorel TM 55 CAPACITY trials 55 standard chemotherapy regimen 55 huN# DM1 55 Aggrastat ® tirofiban hydrochloride 55 GLYX 55 PDE4 inhibitor 55 PS# [001] 55 Multiple Ascending Dose 55 oral deforolimus 55 Endeavor DES 55 histamine dihydrochloride 55 Microplasmin 55 Phase IIa clinical trials 55 FDA Investigational Device 55 #F FDG PET 55 NeuVax 55 Levacor 55 Cleviprex TM clevidipine 55 celgosivir 55 CLL8 55 PROTECT AF 55 sustained virological response 55 Duromist ™ 55 recurrent metastatic 55 IMPACT DCM clinical 55 Symadex 55 vicriviroc 55 APEX AMI 55 SYNTAX 55 Ambulatory Blood Pressure 55 sorafenib tablets 55 Endovascular System 55 Miracor 55 Carotid Revascularization Endarterectomy vs. 55 SNT-MC#/idebenone 55 #mg QD [002] 55 Phase III placebo controlled 55 prospectively defined 55 randomized controlled multicenter 55 APTIMA HPV 55 obatoclax 55 AERx iDMS 55 LCP AtorFen 55 PRT# 55 MVA MUC1 IL2 55 OMS# 55 Zevalin consolidation 55 pharmacodynamic parameters 55 PROVENGE sipuleucel T 55 Ceflatonin 55 CAPHOSOL R 55 NuroPro R 55 ENRICH trial 55 Fodosine 55 vismodegib 55 octreotide implant 55 NuroPro PD 55 PROTECT II 55 PROTEGE 55 Xeloda ® 55 Cervista HPV 55 HF ACTION 55 Fondaparinux 55 DP b# 55 PEGylated interferon 55 confirmatory pivotal 55 PROCHYMAL 55 ANTEGREN 55 modified REGENESIS Phase IIb 55 DOXIL 55 Microvolt T Wave Alternans 55 GALNS 55 Endeavor Drug Eluting 55 PreCISe study 55 Carotid Endarterectomy 55 relapsed MCL 55 PREVAIL 55 ECASS 55 Stragen 55 logistic regression models 55 TYKERB 55 IPL# 55 CRp 55 Echocardiographic 55 MOZOBIL 55 Troxatyl 55 IPLEX 55 PLAC test 55 Phase III Clinical Trials 55 ACOMPLIA R 55 DCVax ® Brain 55 Post hoc 55 Preliminary metallurgical 55 aclidinium bromide 55 TQT studies 55 CCX# B 55 CCR5 inhibitor 55 CALERIE 55 Ocrelizumab 55 QOPI 55 RSD# oral 55 Meta analyzes 55 tipranavir r 55 Phase III registrational 55 phase III ACCLAIM 55 TMC# C# 55 thromboembolic complications 55 refractory AML 55 Breast Cancer Assay 55 satraplatin Phase 55 PRESEPT Study 55 briakinumab 55 Antigen CEA 55 prospective randomized controlled 55 Xinlay 55 Bioequivalence 55 PhG alpha 1 55 Virtual Histology 54 FOLPI 54 Amplimexon 54 midstage clinical 54 Embolic Protection Device 54 budesonide MMX 54 NeuroStar TMS Therapy 54 Powerlink XL 54 TORISEL 54 Zemplar Capsules 54 NATRECOR R 54 PrevOnco 54 Clinicaltrials.gov 54 aflibercept 54 initiate Phase IIb 54 BioNumerik 54 ORBIT II 54 NCT# ClinicalTrials.gov 54 NicOx commented 54 SELDI TOF MS 54 Activity Assay 54 OVA1 ® 54 Tracleer r 54 CCX# 54 ISTODAX 54 cinacalcet 54 ATIR 54 subcutaneous PRO 54 HORIZONS AMI 54 Combo Stent 54 Zerenex 54 PRE SURGE